Langlais P J, Zhang S X, Weilersbacher G, Hough L B, Barke K E
Department of Psychology, San Diego State University, CA 92182.
J Neurosci Res. 1994 Aug 1;38(5):565-74. doi: 10.1002/jnr.490380509.
Three experiments were conducted to examine the role of histamine in neuronal degeneration in a rat model of Wernicke's encephalopathy induced by an acute bout of pyrithiamine-induced thiamine deficiency (PTD). In the first experiment, histamine levels in medial thalamus of freely moving PTD rats measured by microdialysis were increased (180% of controls) at a prelesion stage of thiamine deficiency (treatment day 12) and further elevated 48 hr later (380%) in the same animals when necrosis was evident. Histamine levels in dialysates of the hippocampus collected simultaneously from the same animals were unchanged at either stage of thiamine deficiency. Glutamate levels in microdialysates from the same animals were unchanged at the prelesion stage but were significantly elevated on the second collection day. In a second experiment, separate groups of PTD and pairfed control (CT) rats were infused continuously with either alpha-fluoromethylhistidine (FMH; 80 mg/day, i.p.), an irreversible inhibitor of histamine synthesis, or saline. FMH pretreatment produced a significant protection against PTD-induced neuronal loss within the midline-intralaminar and anteromedial thalamic nuclei, but had no effect on damage to ventrolateral nuclei, anteroventral nucleus, or the mammillary bodies. In a third study, histamine (80 micrograms, free base) or vehicle was directly infused into the same region of medial thalamus dialyzed in experiment 1. Histamine infusion into prelesion PTD but not CT animals resulted in severe neuronal loss and gliosis. Infusion of vehicle into the same regions of PTD and CT rats produced a mild gliosis restricted to the needle tract with no evidence of neuronal loss. These observations together with recent evidence of a histamine enhancement of glutamate receptor activation suggest that early histamine release may contribute significantly to glutamate-N-methyl-D-aspartate (NMDA)-mediated excitotoxic neuronal death in thiamine deficiency-induced Wernicke's encephalopathy.
进行了三项实验,以研究组胺在由急性硫胺素缺乏(PTD)诱发的韦尼克脑病大鼠模型中神经元变性中的作用。在第一个实验中,通过微透析测量的自由活动的PTD大鼠内侧丘脑的组胺水平在硫胺素缺乏的病变前期(治疗第12天)升高(为对照组的180%),在同一动物坏死明显时,48小时后进一步升高(为对照组的380%)。同时从同一动物收集的海马透析液中的组胺水平在硫胺素缺乏的任何阶段均未改变。同一动物微透析液中的谷氨酸水平在病变前期未改变,但在第二次收集日显著升高。在第二个实验中,将单独的PTD组和配对喂养的对照(CT)大鼠组连续注入组胺合成的不可逆抑制剂α-氟甲基组氨酸(FMH;80毫克/天,腹腔注射)或生理盐水。FMH预处理对PTD诱导的中线-板内核和丘脑前内侧核内的神经元损失产生了显著保护作用,但对腹外侧核、前腹核或乳头体的损伤没有影响。在第三项研究中,将组胺(80微克,游离碱)或载体直接注入实验1中进行透析的内侧丘脑的同一区域。向病变前期的PTD动物而非CT动物注入组胺导致严重的神经元损失和胶质增生。向PTD和CT大鼠的同一区域注入载体产生了局限于针道的轻度胶质增生,没有神经元损失的迹象。这些观察结果以及最近关于组胺增强谷氨酸受体激活的证据表明,早期组胺释放可能在硫胺素缺乏诱导的韦尼克脑病中显著促成谷氨酸-N-甲基-D-天冬氨酸(NMDA)介导的兴奋性毒性神经元死亡。